Trial Profile
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs AB-8939 (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors AB Science
- 08 Mar 2024 According to a AB Science media release,the phase 1 is expected to be completed in 2024 and a phase 2 will be initiated in 2025 with an intention to design the study to support accelerated approval.
- 06 Oct 2023 Planned End Date changed from 30 Jun 2023 to 1 Dec 2024.
- 06 Oct 2023 Planned primary completion date changed from 30 Jun 2023 to 1 Dec 2024.